Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSE(S) OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2

NCT04955626 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT04955626
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04955626 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSE(S) OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2
Lead sponsor
BioNTech SE
Phase
Phase 3
Overall status
Completed
Start date
July 1, 2021
Completion date
May 25, 2023
Enrollment
16,372 (actual)
Sites
154

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars-cov-2 infection